Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.
June 1, 2026 02:58 AM EDT
Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
Reynald Castaneda
Deputy Editor
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase …
Diabetic macular edema eye drop from Oculis fails to meet primary endpoint
Why Is Oculis Stock Sinking Monday? - Oculis Holding (NASDAQ:OCS)
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)
Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns
Brimonidine drop with sodium hyaluronate noninferior to Lumify for redness
Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary…
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)
Trials of vision-improving substances are showing good results, though so far only two have been authorized for use in the United…
Studies show that GLP-1 receptor agonists have significant potential for treating glaucoma, diabetic retinopathy and other eye…
I farmaci antidiabetici orali tipo semaglutide possono causare una grave neurite ottica ischemica anteriore con compromissione…
